Specification of Drug Substances and Products
Development and Validation of Analytical Methods
- 1st Edition - October 23, 2013
- Imprint: Elsevier
- Editors: Christopher M. Riley, Thomas W. Rosanske
- Language: English
- Paperback ISBN:9 7 8 - 0 - 0 8 - 1 0 1 3 1 3 - 7
- Hardback ISBN:9 7 8 - 0 - 0 8 - 0 9 8 3 5 0 - 9
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 9 8 3 4 3 - 1
Specification of Drug Substances and Products: Development and Validation of Analytical Methods is a comprehensive and critical analysis of the requirements and approache… Read more
Purchase options
Specification of Drug Substances and Products: Development and Validation of Analytical Methods is a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development and validation of analytical methods. This book is intended as more than a review of new regional guidelines, existing regulatory guidance, and industry practices. It provides a hands-on guide to understanding and applying these in practice. The authors discuss critical issues, novel approaches, and future directions while also providing insight into how International Guidelines were developed and the rationale behind them.
- Guide to industry best practices of analytical methodologies used in the specification of new drug substances and products (e.g. DOE, QbD)
- Critical assessment of the application of ICH guidelines on method validation and specification setting, written by experts involved in the development and application of the guidelines to aid understanding of requirements and what is expected by regulatory authorities
- Direct applicability to the day-to-day activities in drug development and the potential to increase productivity
Designed for use in laboratories and offices as a guidebook, which could be read from cover-to-cover and a comprehensive source of information for those active in the analysis of pharmaceuticals.
- Edition: 1
- Published: October 23, 2013
- Imprint: Elsevier
- Language: English
CR
Christopher M. Riley
Dr. Christopher Riley is the President of Riley and Rabel Consulting Services. He received a bachelor’s degree in Pharmacy (1977) and PhD degree in Pharmaceutical Chemistry (1980) from the University of Bath, UK. He taught Pharmaceutical Chemistry, at the Universities of Florida (1983-6) and the University of Kansas (1986-94), and was a Vice President at DuPont Merck (1994-2001) and ALZA (a division of J&J) (2001-7). He has coauthored more than 140 book chapters and papers in peer-reviewed journals, as well as 5 books. He has extensive experience in CMC regulatory affairs and the development of all types of dosage forms.
Affiliations and expertise
President of Riley and Rabel Consulting Services, Maryville, MO, USATR
Thomas W. Rosanske
Former Director of Business Development at Acceleration Laboratory Services, Incorporated. He has previously held scientific and senior management positions at The Upjohn Company, Marion Laboratories, Marion Merrell Dow, Hoechst Marion Roussel, Quintiles, Eli Lilly, Beckloff Associates, and PPD. He currently serves on a Small Molecule USP Expert Committee.
Affiliations and expertise
Consultatnt, Lee's Summit, MO, USARead Specification of Drug Substances and Products on ScienceDirect